Trial intelligence / Profile preview

Phase 3 trial of risk-adapted therapy for pediatric and young adult primary malignant liver tumors

2023-000036-30Phase 3Active

Sponsor: Medical University of Gdańsk
Start: Feb 2023
Modality: DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
Countries: 1

Overview

Phase 3, open-label, single-arm trial of cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine and 5 more in hepatoblastoma and hepatocellular carcinoma (HCC), sponsored by Medical University of Gdańsk. Primary endpoint: Study completion status. Started Feb 2023; status: active.

Drugs

cisplatincarboplatindoxorubicinfluorouracilvincristine

Conditions

hepatoblastomahepatocellular carcinoma (HCC)

Beyond the preview

Go deeper on 2023-000036-30.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2023-000036-30.